Literature DB >> 22361086

Cost comparison of nephron-sparing treatments for cT1a renal masses.

Scott M Castle1, Vladislav Gorbatiy, Michael A Avallone, Ahmed Eldefrawy, Darryl E Caulton, Raymond J Leveillee.   

Abstract

OBJECTIVES: Treatment options for small renal tumors have evolved from radical nephrectomy (RN) to partial nephrectomy (PN), thermal ablation, or active surveillance. With the advancement of techniques, costs differences are unclear. The objective of this study is to compare the 6-month costs associated with nephron-sparing procedures for cT1a renal tumors.
MATERIALS AND METHODS: We performed a review of patients diagnosed with a solitary cT1a renal mass who underwent surgical treatment from June 2008 to May 2011. Open partial nephrectomy (OPN), robot-assisted partial nephrectomy (RLPN), laparoscopic radio-frequency ablation (LRFA), or computed tomography guided radio frequency ablation (CTRFA) was performed on 173 patients. Cost data were collected for surgical costs, associated hospital stay, and the 6-month postoperative period.
RESULTS: Patients underwent surgery, including 52 OPN, 48 RLPN, 44 LRFA, and 29 CTRFA. Median total costs associated were $17,018, $20,314, $13,965, and $6,475, for OPN, RLPN, LRFA, and CTRFA, respectively. When stratified by approach differences were noted for total cost (P < 0.001), operating room (OR) time (P < 0.001), surgical supply (P < 0.001), and room and board (P < 0.001) in univariable analysis. Multivariable linear regression (R(2) = 0.966) showed surgical approach (P = 0.007), length of stay (P < 0.001), and OR time (P < 0.001) to be significant predictors of total cost. However, tumor size (P = 0.175), and Charlson comorbidity index (P = 0.078) were not statistically significant.
CONCLUSIONS: Six-month cost of nephron-sparing surgery is lowest with radio frequency ablation (RFA) by either laparoscopic or computed tomography (CT)-guided approach compared to RLPN and OPN. As oncologic and safety outcomes improve and become comparable in all nephron-sparing surgery (NSS) approaches, cost of each procedure will start to play a stronger role in the clinical and healthcare policy setting.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cost; Partial nephrectomy; Renal ablation; Renal mass

Mesh:

Year:  2012        PMID: 22361086     DOI: 10.1016/j.urolonc.2012.01.006

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  11 in total

1.  [Percutaneous CT-guided radiofrequency ablation for small renal masses : A retrospective, single center data analysis].

Authors:  O Heißler; S Seklehner; H Fellner; P F Engelhardt; A Chemelli; C Riedl
Journal:  Urologe A       Date:  2018-07       Impact factor: 0.639

2.  Microwave ablation of malignant renal tumours: intermediate-term results and usefulness of RENAL and mRENAL scores for predicting outcomes and complications.

Authors:  Anna Maria Ierardi; Alessio Puliti; Salvatore Alessio Angileri; Mario Petrillo; Ejona Duka; Chiara Floridi; Michela Lecchi; Gianpaolo Carrafiello
Journal:  Med Oncol       Date:  2017-04-19       Impact factor: 3.064

Review 3.  Open partial nephrectomy: ancient art or currently available technique?

Authors:  Mauro Seveso; Fabio Grizzi; Giorgio Bozzini; Alberto Mandressi; Giorgio Guazzoni; Gianluigi Taverna
Journal:  Int Urol Nephrol       Date:  2015-10-05       Impact factor: 2.370

Review 4.  Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy.

Authors:  Serge Ginzburg; Jeffrey J Tomaszewski; Alexander Kutikov
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

5.  Evaluation of the Clinical Use of Robot-Assisted Retroperitoneal Laparoscopy and Preoperative RENAL Scoring for Nephron Sparing Surgery in Renal Tumor Patients.

Authors:  Yu Xia; Gong-Xian Wang; Bin Fu; Wei-Peng Liu; Cheng Zhang; Xiao-Chen Zhou
Journal:  Indian J Surg       Date:  2016-12-26       Impact factor: 0.656

Review 6.  Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards.

Authors:  Julie Cronan; Sean Dariushnia; Zachary Bercu; Robert Mitchell Ermentrout; Bill Majdalany; Laura Findeiss; Janice Newsome; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

Review 7.  Microwave ablation of renal tumors: state of the art and development trends.

Authors:  Chiara Floridi; Irene De Bernardi; Federico Fontana; Alessandra Muollo; Anna Maria Ierardi; Andrea Agostini; Paolo Fonio; Ettore Squillaci; Luca Brunese; Carlo Fugazzola; Gianpaolo Carrafiello
Journal:  Radiol Med       Date:  2014-07-08       Impact factor: 3.469

Review 8.  The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation.

Authors:  Tobias Klatte; Nils Kroeger; Uwe Zimmermann; Martin Burchardt; Arie S Belldegrun; Allan J Pantuck
Journal:  World J Urol       Date:  2014-04-04       Impact factor: 4.226

Review 9.  Image-guided minimally invasive treatment for small renal cell carcinoma.

Authors:  Miltiadis E Krokidis; Panagiotis Kitrou; Stavros Spiliopoulos; Dimitrios Karnabatidis; Konstantinos Katsanos
Journal:  Insights Imaging       Date:  2018-04-06

10.  Radiofrequency ablation of small renal masses in comorbid patients.

Authors:  Jerzy Siekiera; Milosz Jasinski; Witold Mikołajczak
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-03-21       Impact factor: 1.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.